Esperion Therapeutics, Inc. (0IIM.L)
USD 1.3
(-1.19%)
USD 1.3
(-1.19%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 501.54 Million USD | 92.48% |
| 2022 | 260.56 Million USD | 0.68% |
| 2021 | 258.8 Million USD | 41.56% |
| 2020 | 182.82 Million USD | 16385.21% |
| 2019 | 1.1 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 1.02 Million USD | -61.98% |
| 2015 | 2.68 Million USD | -37.47% |
| 2014 | 4.29 Million USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 7.52 Million USD | 9.16% |
| 2011 | 6.89 Million USD | 0.0% |
| 2002 | 7.73 Million USD | 41.03% |
| 2001 | 5.48 Million USD | 81.1% |
| 2000 | 3.02 Million USD | 32.54% |
| 1999 | 2.28 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 517.22 Million USD | -47.34% |
| 2024 Q1 | 498.43 Million USD | -0.62% |
| 2023 Q3 | 263.21 Million USD | 0.29% |
| 2023 FY | 501.54 Million USD | 92.48% |
| 2023 Q4 | 501.54 Million USD | 90.55% |
| 2023 Q2 | 262.44 Million USD | 0.51% |
| 2023 Q1 | 261.09 Million USD | 0.2% |
| 2022 Q3 | 259.53 Million USD | 0.12% |
| 2022 FY | 260.56 Million USD | 0.68% |
| 2022 Q4 | 260.56 Million USD | 0.4% |
| 2022 Q2 | 259.21 Million USD | 0.11% |
| 2022 Q1 | 258.94 Million USD | 0.05% |
| 2021 Q4 | 258.8 Million USD | -5.48% |
| 2021 FY | 258.8 Million USD | 41.56% |
| 2021 Q3 | 273.82 Million USD | -0.07% |
| 2021 Q2 | 274.01 Million USD | -0.07% |
| 2021 Q1 | 274.21 Million USD | 49.99% |
| 2020 Q1 | 3.71 Million USD | 235.35% |
| 2020 Q3 | 4.1 Million USD | 3.48% |
| 2020 FY | 182.82 Million USD | 16385.21% |
| 2020 Q2 | 3.96 Million USD | 6.67% |
| 2020 Q4 | 182.82 Million USD | 4353.62% |
| 2019 Q3 | 820 Thousand USD | 8.04% |
| 2019 Q4 | 1.1 Million USD | 35.24% |
| 2019 FY | 1.1 Million USD | 0.0% |
| 2019 Q1 | 792 Thousand USD | 0.0% |
| 2019 Q2 | 759 Thousand USD | -4.17% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | 140 Thousand USD | -76.07% |
| 2017 Q1 | 585 Thousand USD | -42.76% |
| 2017 FY | - USD | -100.0% |
| 2017 Q3 | - USD | -100.0% |
| 2016 Q1 | 2.28 Million USD | -15.07% |
| 2016 FY | 1.02 Million USD | -61.98% |
| 2016 Q4 | 1.02 Million USD | -29.57% |
| 2016 Q2 | 1.87 Million USD | -18.05% |
| 2016 Q3 | 1.45 Million USD | -22.45% |
| 2015 Q4 | 2.68 Million USD | -12.84% |
| 2015 FY | 2.68 Million USD | -37.47% |
| 2015 Q1 | 3.85 Million USD | -10.33% |
| 2015 Q2 | 3.47 Million USD | -9.91% |
| 2015 Q3 | 3.08 Million USD | -11.2% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | 4.67 Million USD | -5.0% |
| 2014 Q4 | 4.29 Million USD | -8.06% |
| 2014 FY | 4.29 Million USD | 0.0% |
| 2014 Q2 | 4.92 Million USD | 0.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | -100.0% |
| 2012 Q4 | 7.52 Million USD | 0.0% |
| 2012 FY | 7.52 Million USD | 9.16% |
| 2011 FY | 6.89 Million USD | 0.0% |
| 2003 Q1 | 7.72 Million USD | -0.13% |
| 2003 Q3 | 8.07 Million USD | 1.59% |
| 2003 Q2 | 7.94 Million USD | 2.94% |
| 2002 FY | 7.73 Million USD | 41.03% |
| 2002 Q2 | 7.43 Million USD | 7.46% |
| 2002 Q3 | 7.22 Million USD | -2.9% |
| 2002 Q1 | 6.92 Million USD | 26.25% |
| 2002 Q4 | 7.73 Million USD | 7.06% |
| 2001 Q2 | 5.12 Million USD | 55.1% |
| 2001 Q4 | 5.48 Million USD | 1.78% |
| 2001 FY | 5.48 Million USD | 81.1% |
| 2001 Q1 | 3.3 Million USD | 9.25% |
| 2001 Q3 | 5.38 Million USD | 5.01% |
| 2000 Q1 | 2.12 Million USD | 0.0% |
| 2000 FY | 3.02 Million USD | 32.54% |
| 2000 Q2 | 1.97 Million USD | -6.99% |
| 2000 Q3 | 2.48 Million USD | 25.72% |
| 2000 Q4 | 3.02 Million USD | 21.91% |
| 1999 FY | 2.28 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -285.612% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -780.091% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -29.312% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -997.643% |
| bluebird bio, Inc. | 224.41 Million USD | -123.486% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -1252.642% |
| Imunon, Inc. | 1.13 Million USD | -43922.565% |
| Editas Medicine, Inc. | 24.37 Million USD | -1957.878% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 96.129% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 74.612% |
| Myriad Genetics, Inc. | 130.9 Million USD | -283.152% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -94.172% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1410.863% |
| Verastem, Inc. | 40.08 Million USD | -1151.175% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 93.765% |
| Waters Corporation | 2.3 Billion USD | 78.246% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 98.398% |
| Biogen Inc. | 7.18 Billion USD | 93.023% |
| Nektar Therapeutics | 112.62 Million USD | -345.324% |
| Perrigo Company plc | 3.63 Billion USD | 86.194% |
| Dynavax Technologies Corporation | 252.41 Million USD | -98.697% |
| Illumina, Inc. | 1.48 Billion USD | 66.317% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -15386.358% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -50054.6% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -188.655% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -2030.702% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 15.436% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -1396.482% |
| Evolus, Inc. | 120.35 Million USD | -316.708% |
| Adicet Bio, Inc. | 17.7 Million USD | -2733.113% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -16215.745% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 81.444% |
| FibroGen, Inc. | 89.69 Million USD | -459.156% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 81.662% |
| OPKO Health, Inc. | 222.03 Million USD | -125.887% |
| Homology Medicines, Inc. | 43.17 Million USD | -1061.631% |
| Geron Corporation | 35.05 Million USD | -1330.904% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 78.594% |
| Exelixis, Inc. | 189.94 Million USD | -164.049% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -53483.974% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -418.41% |
| Zoetis Inc. | 6.56 Billion USD | 92.359% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -181.657% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -11293.594% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 30.793% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1366.938% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 64.185% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 55.714% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 66.547% |
| Blueprint Medicines Corporation | 610.96 Million USD | 17.909% |
| Insmed Incorporated | 1.19 Billion USD | 57.972% |
| TG Therapeutics, Inc. | 100.11 Million USD | -400.955% |
| Incyte Corporation | 29.16 Million USD | -1619.861% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -12.328% |